Orthocell Ltd has released a press release.
Another Record Revenue Quarter for Orthocell
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Orthocell
- First Distributor signed for Remplir in $75m Canadian Market
- Globally Significant Opportunity Emerges as Remplir™ is used in Nerve-Sparing Prostate Cancer Surgery
- Remplir Use in Prostate Surgery Signals Global Opportunity
- Remplir™ Study Delivers Compelling 81% Success Rate
- Compelling 81% Success Rate for Remplir
Later from Orthocell
- Trading Halt
- $30m Placement Sees Orthocell Positioned for Rapid Growth
- OCC Secures Rights to High-Value Bone Regeneration Tech
- HK Distributor Signed as Remplir Expands in the Asian Market
- Remplir Launches in Hong Kong with First Surgical Case
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell